BioSpace News Archive

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced its unaudited financial results for the quarter ended June 30, 2022.

Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced financial results for the second quarter ended June 30, 2022.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the second quarter ended June 30, 2022.

Eledon Pharmaceuticals, Inc. reported its second quarter 2022 operating and financial results and reviewed recent business highlights.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Trapelo Health announced a first-of-its-kind collaboration with Texas Oncology and Superior HealthPlan aimed at bringing the latest advancements in precision oncology to more cancer patients throughout Texas.

The global biomarker testing services market is expected to register significant growth in the forecast period.

According to Vision Research Reports, the global cell and gene therapy market size is expected to hit around USD 42.56 billion by 2030, growing at a CAGR of 39.42 % during the forecast period 2022 to 2030.

The global cellular immunotherapy market was surpassed at USD 6.22 billion in 2021 and is expected to hit around USD 38.2 billion by 2030, growing at a CAGR of 22.34% from 2022 to 2030.

According to Latest Study, the global glaucoma surgery devices market was valued at USD 15 billion in 2021 and it is predicted to surpass around USD 3.16 billion by 2030 with a CAGR of 7.7% from 2022 to 2030